- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03692039
Comparison Between M-Pro and ProTaper Next
July 13, 2020 updated by: Mohammed Essam Othman Ibrahim, Cairo University
Comparison of Postoperative Pain After Root Canal Instrumentation Using M-Pro and ProTaper Next in Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial
Comparing the postoperative pain resulting after mechanical instrumentation using M-pro files versus that resulting after using ProTaper Next rotary files in lower molar with symptomatic Irreversible pulpitis molars.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Lower molars with symptomatic Irreversible pulpitis molars are selected according to the eligibility and exclusion criteria and patients are then randomized to receive treatment either using M-pro Files or ProTaper Next files.
Postoperative pain is then assessed using the Numerical Rating scale 6, 12, 24, 48 and 72 hours post-operatively .
After completing the treatment, patients will instructed to take placebo if they feel pain and will be asked to provide the quantity of placebo intake until 72 hrs.
In case of pain not relieved by placebo, after recording the amount of pain, the patient will be instructed to take an alternative line of pain control (Ibuprofen 400mg tablets every 6 hours).
The amount and frequency of Ibuprofen intake will be recorded.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt, 52431
- Faculty of Dentistry - Cairo University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1- Males or Females.
2- Mandibular molar teeth with:
- Pre-operative sharp pain.
- Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).
- Normal periapical radiographic appearance or slight widening in lamina dura using periapical index (PAI) score 1 as normal periapical structures or 2 as small changes in bone structures.
Exclusion Criteria:
- Patients having significant systemic disorders.
- Patients who are allergic to non-steroidal anti-inflammatory drugs.
- Patients with two or more adjacent teeth requiring root canal therapy.
Teeth that have:
- Necrotic pulp tissues.
- Association with swelling or fistulous tract.
- Acute or chronic peri-apical abscess.
- Greater than grade I mobility.
- Pocket depth greater than 5mm.
- No possible restorability.
- Previous endodontic treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: M-pro files
Instrumentation using M-pro files in rotating motion
|
An endodontic file that has controlled memory properties
|
|
Active Comparator: ProTaper Next files
Instrumentation using ProTaper Next files in rotating motion
|
An endodontic file that has an off center mass of rotation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post operative pain assessed with numerical rating scale
Time Frame: Up to 72 hours post-operatively
|
0 (none) to 10 (severe) Numerical Pain Rating Scale up to 72 hours post-operatively
|
Up to 72 hours post-operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of placebo intake assessed by questioning
Time Frame: Up to 72 hours post-operatively
|
Amount of placebo intake up to 72 hours post-operatively
|
Up to 72 hours post-operatively
|
|
Amount of analgesic intake assessed by counting
Time Frame: Up to 72 hours post-operatively
|
Number of analgesic tablets up to 72 hours post-operatively
|
Up to 72 hours post-operatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kocak MM, Cicek E, Kocak S, Saglam BC, Furuncuoglu F. Comparison of ProTaper Next and HyFlex instruments on apical debris extrusion in curved canals. Int Endod J. 2016 Oct;49(10):996-1000. doi: 10.1111/iej.12552. Epub 2015 Oct 12.
- Ruddle CJ, Machtou P, West JD. The shaping movement: fifth-generation technology. Dent Today. 2013 Apr;32(4):94, 96-9. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2018
Primary Completion (Actual)
October 1, 2019
Study Completion (Actual)
October 1, 2019
Study Registration Dates
First Submitted
September 29, 2018
First Submitted That Met QC Criteria
October 1, 2018
First Posted (Actual)
October 2, 2018
Study Record Updates
Last Update Posted (Actual)
July 14, 2020
Last Update Submitted That Met QC Criteria
July 13, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEBD-CU-2018-09-33
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Irreversible Pulpitis
-
Tehran University of Medical SciencesActive, not recruitingSymptomatic Irreversible Pulpitis (SIP) | Symptomatic Irreversible Pulpitis With Apical PeridontitisIran
-
Zahoor khanHITEC-Institute of Medical SciencesCompletedEvaluating the Combined Effect of Oral Premedications on Inferior Alveolar Nerve Block EffectivenessSymptomatic Irreversible PulpitisPakistan
-
HITEC-Institute of Medical SciencesRecruitingSymptomatic Irreversible PulpitisPakistan
-
Ondokuz Mayıs UniversityRecruitingSymptomatic Irreversible Pulpitis (SIP)Turkey (Türkiye)
-
Cairo UniversityNot yet recruitingSymptomatic Irreversible Pulpitis (SIP)Egypt
-
Future University in EgyptActive, not recruitingSymptomatic Irreversible Pulpitis (SIP)Egypt
-
Dow University of Health SciencesRecruitingSymptomatic Irreversible Pulpitis (SIP)Pakistan
-
Cairo UniversityCompletedSymptomatic Irreversible Pulpitis (SIP)Egypt
-
Hadeer Mostafa El Mohamady El FekyNot yet recruitingSymptomatic Irreversible Pulpitis With Apical PeridontitisEgypt
-
University of FujairahRecruitingSymptomatic Irreversible Pulpitis | Symptomatic Irreversible Pulpitis (SIP)United Arab Emirates
Clinical Trials on M-pro files in rotating motion
-
Poznan University of Medical SciencesCompletedCardiovascular Diseases | Inflammation | Chronic Kidney Diseases | Dialysis; Complications | Atherosclerosis of ArteryPoland